InteRNA Technologies awarded €1.3m Innovation Credit

Published: 17-Nov-2010
Research & Development Finance

Will support development of therapeutics to treat melanoma


InteRNA Technologies, a Dutch biopharmaceutical company developing pathway targeted microRNA (miRNA)-based therapeutics for cancer, has been awarded an Innovation Credit of €1.3m from the Dutch government.

The company says the award will support the development of miRNA-based therapeutics for the treatment of melanoma. Agentschap, an agency of the Dutch Ministry of Economic Affairs, Agriculture and Innovation, granted the funding.

The Innovation Credit is aimed at funding development projects with a high innovative character and strong commercial potential.

Roel Schaapveld, chief executive of InteRNA Technologies said: ‘It allows us to further strengthen the r&d team and speed up the development of our miRNA-based therapy to treat more advanced stages of this aggressive form of cancer for which there currently is no adequate treatment.’

The Innovation Credit will become available upon achievement of specific milestones.

  • Companies:
  • InteRNA Technologies
See more

You may also like

Research & Development

OGT launches new SureSeq myeloid fusion panel drive myeloid cancer research

Read more
The assay enables users to integrate research techniques with a single, streamlined NGS process, expediting the process

Trending Articles

  1. COVID-19 still a significant risk for the immunocompromised, study finds AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
  2. Lonza's AI-enabled small molecule development tool launches The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
  3. N4 Pharma and SRI to target and treat previously unreachable human cells The companies will collaborate to perform research to conjugate SRI’s MGS system to Nuvec to increase intracellular delivery to specific target cells.
  4. Miltenyi Biotec and MiLaboratories collaborate to advance next-generation therapies Miltenyi Biotec will commercialise MiLaboratories' RNA kit technology for immune sequencing, facilitating advances in the field of personalised medicine
  5. Compact process thermostat for efficient temperature control in the lab The Petite Fleur allows for laboratory reactor temperature control between -40 °C to +200 °C with a 480W refrigeration capacity

Upcoming event

ASGCT Annual Meeting 2024

7-11 May, 2024 | Meeting | Portland, OR See all

You may also like

Research & Development

OGT launches new SureSeq myeloid fusion panel drive myeloid cancer research

The assay enables users to integrate research techniques with a single, streamlined NGS process, expediting the process
Regulatory

Compact process thermostat for efficient temperature control in the lab

The Petite Fleur allows for laboratory reactor temperature control between -40 °C to +200 °C with a 480W refrigeration capacity
Research & Development

Lonza's AI-enabled small molecule development tool launches

The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Manufacturing

Miltenyi Biotec and MiLaboratories collaborate to advance next-generation therapies

Miltenyi Biotec will commercialise MiLaboratories' RNA kit technology for immune sequencing, facilitating advances in the field of personalised medicine
Research & Development

Abzena launches EpiScreen 2.0 to assist the development of complex biologics and bioconjugates

The updated platform delivers an advanced range of immune response measurements, while also providing information on mechanism-of-action and specificity
Research & Development

COVID-19 still a significant risk for the immunocompromised, study finds

AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
Research & Development

N4 Pharma and SRI to target and treat previously unreachable human cells

The companies will collaborate to perform research to conjugate SRI’s MGS system to Nuvec to increase intracellular delivery to specific target cells.
Subscribe now